Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05354232 · ClinicalTrials.gov registry record · NA

Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)

A NA study of Attention Deficit Disorder With Hyperactivity and Attention Deficit Disorder, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT05354232: Recruiting NA study of Attention Deficit Disorder With Hyperactivity and Attention Deficit Disorder, sponsored by Massachusetts General Hospital.

NCT05354232 is a NA study of Attention Deficit Disorder With Hyperactivity and Attention Deficit Disorder that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 60 participants, below the 352-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05354232, a NA study of Attention Deficit Disorder With Hyperactivity and Attention Deficit Disorder, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The investigators are investigating whether home-based tDCS over the course of four weeks can improve ADHD symptom severity and improve dysexecutive functioning (cognitive control). Further, the investigators are investigating whether there is a dose-dependent response to tDCS.

Primary Outcome

P300, an electrophysiological feature theorized to represent executive functioning, has been previously shown to be notably diminished during the Erickson Flanker Task (EFT) . We will be administering this task to assess changes in P300 during the EFT, and if any changes are related to subjects' assigned condition.

Interventions

  • DEVICE 2 mA transcranial direct current stimulation (tDCS)
  • DEVICE 1 mA transcranial direct current stimulation (tDCS)
  • DEVICE Sham transcranial direct current stimulation (tDCS)

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Charlestown

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2022-07-01
Est. Completion 2026-05
Phase NA
Massachusetts General Hospital

2,032 total trials

What NCT05354232 shows while recruiting

NCT05354232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 352-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (83% lower).

The record links to 2 conditions, with Attention Deficit Disorder With Hyperactivity appearing as the primary indexed condition, and to 3 interventions - of which 2 mA transcranial direct current stimulation (tDCS) is the first listed.

NCT05354232 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05354232 about?

NCT05354232 is a clinical study titled "Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)". The investigators are investigating whether home-based tDCS over the course of four weeks can improve ADHD symptom severity and improve dysexecutive functioning (cognitive control). Further, the investigators are investigating whether there is a dose-dependent response to tDCS.

What is the current status of trial NCT05354232?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2022-07-01. Estimated completion is 2026-05.

What conditions does trial NCT05354232 study?

This clinical trial studies the following conditions: Attention Deficit Disorder With Hyperactivity, Attention Deficit Disorder.

What interventions are being tested in trial NCT05354232?

The interventions under investigation include: 2 mA transcranial direct current stimulation (tDCS) (DEVICE), 1 mA transcranial direct current stimulation (tDCS) (DEVICE), Sham transcranial direct current stimulation (tDCS) (DEVICE).

Who is sponsoring clinical trial NCT05354232?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05354232 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Attention Deficit Disorder With Hyperactivity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05354232's enrollment target sits among peer trials

60 15th of 20 higher than 5 of 20 other Attention Deficit Disorder With Hyperactivity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Attention Deficit Disorder With Hyperactivity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05354232, the US trial registry maintained by the National Library of Medicine. NCT05354232 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.